Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data SANGAMO THERAPEUTICS, INC files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
19.4
36.6
84.5
102
118
111
111
176
57.8
39.6
Research and development
65.6
65.7
115
146
181
231
250
234
112
113
General and administrative
26.3
27.2
46.7
61.7
67.1
63.2
62.7
61.2
44.7
34.9
Operating expenses
91.9
92.9
162
208
248
294
313
450
162
161
Operating income
-72.6
-56.4
-77.2
-105
-130
-183
-201
-274
-104
-121
Interest income
1.51
1.3
Other non-operating income
0.89
4.35
-3.56
Pre-tax income
-71.7
-54.6
-68.9
-95.4
-121
-178
-192
-263
-98.1
-124
Income tax
-0.01
0
0
0
0.35
0.31
0.43
-5.07
-0.17
-0.57
Net income to minority interests
0
-0.56
-0.23
-0.13
-0.01
0
0
Net income
-71.7
-54.6
-68.3
-95.2
-121
-178
-192
-258
-97.9
-123
EBITDA
-71.6
-54.9
-74.8
-101
-124
-174
-189
-259
-98.9
-117
EPS, basic
-1.02
-0.70
-0.70
-0.85
-0.90
-1.23
-1.25
-1.48
-0.49
-0.44
EPS, diluted
-1.02
-0.70
-0.70
-0.85
-0.90
-1.23
-1.25
-1.48
-0.49
-0.44
Shares, basic (weighted)
70.6
78.1
96.9
112
134
145
154
174
202
280
Shares, diluted (weighted)
70.6
78.1
96.9
112
134
145
154
174
202
280
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
22.1
49.8
140
80.4
131
179
100
45.2
41.9
20.9
Short-term investments
193
260
282
510
198
177
Receivables
4.97
3.34
4.67
36.9
5.22
6.01
3.68
0.92
0.53
0.37
Other current assets
1.85
1.51
5.34
5.41
12
15.9
18.2
9.26
5.18
4.37
Total current assets
150
248
411
405
660
399
300
94.3
51.7
35.8
Property, plant and equipment
6.56
31.1
78.7
29.9
41.3
51.5
63.5
26.9
17.9
11
Lease right-of-use assets
0
77.3
71
73.2
62
26
16.9
3.06
Goodwill
1.59
1.59
40
39.3
42.8
39.7
37.6
0
0
Intangible assets
0
54.2
53.2
58.1
53.8
50.7
0
0
Long-term investments
1.01
0
21.8
50.5
88.2
29.8
Other non-current assets
0.17
1.18
3.36
9.07
13.6
15.3
17
1.27
0.88
0.87
Total assets
158
287
590
638
939
722
563
165
102
59.7
Accounts payable
2.58
0.02
3.36
6.67
12.6
9.76
22.4
15.3
15.5
14.4
Accrued liabilities
10.9
18.6
11.6
16
23.6
8.2
9.41
Deferred revenue
4.15
28.3
47.6
38.7
91.6
85.7
51.8
0
7.56
0.9
Total current liabilities
13.3
44.9
78.5
69.9
144
128
112
47.7
45.8
42.5
Lease liabilities
0
41.2
38.4
44.1
39
33.5
26.3
25.1
Other non-current liabilities
1.96
5.71
7.01
1.22
1.21
1.19
0.93
0.58
Total liabilities
21.7
98.8
223
205
441
347
268
82.4
78.9
74
Paid-in capital
576
683
930
1,091
1,269
1,334
1,450
1,492
1,532
1,611
Retained earnings
-441
-495
-563
-657
-778
-956
-1,149
-1,406
-1,504
-1,627
Other comprehensive income
0.02
-0.29
-1.44
-2.45
5.42
-3.99
-8.4
-4.6
-7.53
-1.46
Shareholders' equity
136
188
367
433
498
375
295
82.9
22.8
-14.3
Minority interests
0
0.74
0.19
-0.87
0
Total equity
136
188
367
433
497
375
295
82.9
22.8
-14.3
Total liabilities and equity
158
287
590
638
939
722
563
165
102
59.7
Shares outstanding
70.9
85.6
102
116
142
146
167
178
213
351
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-71.7
-54.6
-68.9
-95.4
-121
-178
-192
-258
-97.9
-123
Depreciation and amortization
1
1.5
2.36
3.93
5.68
9.44
12.1
15.1
5.11
3.96
Stock-based compensation
15.1
9.09
14.7
19.3
25.7
33
31.7
27.4
12.4
9.08
Deferred income tax
-0.01
0
0
-6.34
0
Change in receivables
-2.14
1.63
-1.33
-32.2
31.7
-0.79
2.34
2.76
0.4
0.16
Change in payables
-2.34
3.22
-6.37
-4.19
10.7
-7.66
13.3
5.59
-14.2
2.79
Cash from operations
-65.9
11.2
36.6
-144
170
-233
-224
-225
-67.1
-97.2
Capital expenditures
-0.73
-3.75
-43.1
-20.7
-14.7
-23.3
-20.2
-21.2
-0.27
-0.1
Acquisitions
0
-75.6
0
0
Purchases of investments
-219
-252
-451
-444
-571
-338
-277
-59.6
0
Sales and maturities of investments
237
179
392
405
315
603
355
19.7
34.7
0
Cash from investing
18.1
-77.4
-178
-59.8
-272
248
59.3
154
37.5
-0.1
Stock issued
1.11
0.82
1.48
2.04
2.02
15.1
21.9
21.5
Cash from financing
0.34
97.5
232
142
153
32.9
84.7
14.6
28.4
70.7
Exchange rate effect
0
0.44
0.18
-0.45
-0.26
1.25
1.48
-2.05
4.09
Net change in cash
-47.4
31.3
90.6
-62
50.9
47.5
-78.4
-55.2
-3.29
-22.5
Free cash flow
-66.6
7.43
-6.52
-165
155
-257
-244
-246
-67.4
-97.3
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to March 31, 2026; growth uses fiscal years. Valuation uses the share price of $0.14 on September 28, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-357.5%
Operating income / revenue.
EBITDA margin
-347.0%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-358.9%
Pre-tax income / revenue.
Net margin
-356.9%
Net income / revenue.
FCF margin
-261.8%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-261.4%
Cash from operations / revenue.
Return on assets (ROA)
-205.7%
Net income / average total assets.
R&D / revenue
327.7%
Research and development expense / revenue.
Stock-based pay / revenue
21.6%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
0.3%
Capital expenditures / revenue.
D&A / revenue
10.6%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-31.6%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-29.2%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
-19.7%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
-162.7%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
-41.2%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-52.6%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-42.4%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
38.9%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
22.0%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
15.8%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.70x
Current assets / current liabilities.
Quick ratio
0.54x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.52x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.09
Revenue / diluted weighted shares.
FCF per share
-$0.23
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.23
Cash from operations / diluted weighted shares.
Book value per share
-$0.05
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
1.69x
Market cap / revenue.
EV/Sales
0.89x
Enterprise value / revenue.
FCF yield
-154.9%
Free cash flow / market cap.
Earnings yield
-211.1%
Net income / market cap (the inverse of P/E).
What was SANGAMO THERAPEUTICS, INC's revenue in fiscal 2025?
SANGAMO THERAPEUTICS, INC reported revenue of $39.6M for fiscal 2025, 31.6% lower than the year before.
Was SANGAMO THERAPEUTICS, INC profitable in fiscal 2025?
No. It reported a net loss of $122.9M.
How much free cash flow did SANGAMO THERAPEUTICS, INC generate in fiscal 2025?
Cash from operations of $97.2M minus capital expenditures of $102.0K left free cash flow of -$97.3M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.